BMAC (bone marrow aspirate concentrate) and MFAT (microfragmented adipose tissue) are the two autologous cell sources, and the cell-content evidence leans one way. Microfragmentation preserves the fat’s perivascular niche, with higher pericyte content and greater secretory activity (Stem Cells Translational Medicine, 2018); donor-matched comparisons report greater proliferation from adipose-derived cells (Stem Cell Research & Therapy, 2018); and adipose cellularity is reported to hold with age while marrow declines. Outcome trials so far read comparable. At Dynamic Athlete in Boulder, Colorado, Aneesh Garg, DO, CAQ weighs cell potential against anatomy, history, and joint, then pairs the selection with high-dose PRP and FRP.
Most of what ranks for this question is journal abstracts and vendor copy. This page translates the same literature into what a patient can use: where the cell evidence points, what the outcome trials add, and why the selection is still made per case.
The Decision
The cell numbers lean MFAT. Richer measured biology and cellularity that holds with age are why fat is frequently the selected source here, especially in later decades.
The lean is not a default. Marrow brings its own cell and signaling profile, some anatomies and histories argue for a pelvic draw over an abdominal one, and the outcome trials read comparable so far. Dr. Garg selects per case, then always pairs the source with high-dose PRP and FRP under live ultrasound.
Key Takeaways
- The cell-potential evidence favors adipose. A preserved niche with higher pericyte content and greater secretory activity, plus greater proliferation in a donor-matched comparison (both 2018, cited below).
- Age strengthens the lean. Reported cell counts in adipose tissue hold up with age, while marrow cellularity tends to decline in later decades.
- The outcome trials so far read comparable. Mautner 2019: both sources improved knee osteoarthritis, no significant difference in that indication. Hohmann 2025 (meta-analysis): no advantage for MFAT over PRP or bone marrow injections.
- Higher potential is not auto-selected. Anatomy, history, and the joint still weigh in. Dynamic Stem Cell+ is physician-selected MFAT or BMA, always paired with high-dose PRP and FRP under live ultrasound.
- In our combined protocols, over 90% of our patients self-report a 75% or greater improvement, all without surgery. HSA and FSA dollars typically apply, and Cherry financing can spread the investment.
MFAT Cell Biology · Stem Cells Translational Medicine 2018
Higher pericyte content
Microfragmentation preserves the adipose perivascular niche: the Vezzani study measured higher pericyte frequency and greater secretory activity in MFAT than in enzymatically processed tissue. More of the repair biology arrives intact.
What actually differs between the two sources?
The layers: cell biology, age, outcomes, then the selection.
The cell-content evidence: adipose leads
The laboratory comparisons lean MFAT. Vezzani (Stem Cells Translational Medicine, 2018): microfragmentation spares the fat’s microvessel architecture, measuring higher pericyte content and greater secretory activity than enzymatically processed tissue. Mohamed-Ahmed (Stem Cell Research & Therapy, 2018), donor-matched: greater proliferation from adipose-derived cells than bone-marrow-derived cells. This is the evidence behind the impression that MFAT carries more cell potential.
Cellularity and age
The two tissues age differently. Published reports describe adipose-derived cell counts holding up with age while bone-marrow cellularity tends to decline in later decades. A 65-year-old and a 35-year-old with the same knee picture may still leave with different selections.
The outcome trials: comparable, in the indication tested
Cell potential has not yet shown up as outcome separation in knee osteoarthritis. Mautner (Stem Cells Translational Medicine, 2019): both sources improved pain and function, no significant difference. Baria (2024, randomized): MFAT equivalent to PRP at 12 months. Hohmann (The American Journal of Sports Medicine, 2025, meta-analysis): no advantage across injection types. Outcomes depend on more than cell count: dose, delivery, indication, and protocol all move the result.
Why the higher-potential source is not automatic
Selection still runs through the exam. Marrow brings its own cell and signaling profile; prior abdominal surgery, body composition, or pelvic anatomy can argue for one harvest over the other; both are same-day, in-clinic draws under local anesthesia. In Dynamic Stem Cell+ the selected source is always paired with high-dose PRP and Exosome-Containing Fibrin-Rich Plasma, under live ultrasound, by Aneesh Garg, DO, CAQ.
How do BMA and MFAT compare side-by-side?
| Property | BMA (Bone Marrow) | MFAT (Adipose) |
|---|---|---|
| Harvest site | Posterior pelvis | Abdomen or flank fat |
| Cell biology | Marrow-derived cells and signaling factors | Higher pericyte content; preserved niche; greater proliferation (reported) |
| Age consideration | Cellularity tends to decline in later decades | Cell counts reported to hold up with age |
| Experience | Local anesthesia; brief pelvic aspiration | Local anesthesia; mini-liposuction style draw |
| Outcome note | Equivalent to PRP at 2 years (randomized, knee OA) | No significant outcome difference vs BMAC (knee OA) |
| In Dynamic Stem Cell+ | Physician-selected; paired with high-dose PRP + FRP | Physician-selected; paired with high-dose PRP + FRP |
The bottom line
If cell content were the whole story, MFAT would be automatic. It is not. The cell evidence favors fat; the outcome trials read comparable; anatomy and history sometimes argue for marrow. Weighing all three layers is the physician’s job.
Which three questions reveal a single-source default?
Print this. Ask it anywhere.
- Is the cell source selected from my imaging, age, and anatomy, or is one source all you offer?
- Who performs the harvest and the injection, and under what image guidance?
- What else is in the protocol besides the cells, stated specifically?
Frequently asked questions
What is the difference between MFAT and BMA?
MFAT (micro-fragmented adipose tissue) is harvested from your own fat, typically the abdomen or flank, and BMA (bone marrow aspirate) is harvested from bone marrow, most often the posterior pelvis. Both are autologous, from your own body, processed in the clinic, and delivered the same day as part of Dynamic Stem Cell+.
How does Dr. Garg decide between MFAT and BMA for a patient?
The decision is physician-selected based on the joint being treated, your imaging, and your overall health profile, not a default choice applied to every patient. Some patients are also better candidates for one harvest site than the other based on prior surgeries or anatomy, which the evaluation identifies.
Does harvesting MFAT or BMA require a hospital stay?
No. Both are performed as an in-clinic, same-day procedure under local anesthesia, not in a hospital or surgical center. Dr. Garg walks you through what to expect for whichever source your evaluation selects, including the harvest, the processing time, and the injection itself.
Is MFAT or BMA combined with anything else in the protocol?
Yes. Dynamic Stem Cell+ always pairs the selected MFAT or BMA with high-dose PRP and Exosome-Containing Fibrin-Rich Plasma, delivered by Dr. Garg under live ultrasound. The stem cell source is one part of the protocol, not the entire treatment.
Is BMAC or MFAT better for knee osteoarthritis?
The answer has two honest layers. On cell biology, the evidence favors MFAT: microfragmentation preserves the adipose perivascular niche with higher pericyte content and greater secretory activity (Stem Cells Translational Medicine, 2018), and donor-matched laboratory comparisons report greater proliferation from adipose-derived cells (Stem Cell Research & Therapy, 2018). On clinical outcomes, the trials so far read comparable: in the Mautner study (2019) both sources improved knee-osteoarthritis pain and function with no significant difference, and a 2025 meta-analysis found no advantage across injection types. So MFAT carries the stronger cell case while outcomes have not yet separated, which is why Aneesh Garg, DO, CAQ selects the source per patient, weighing age, anatomy, and history, and pairs it with high-dose PRP and FRP. Individual results vary.
What is the recovery after an MFAT or BMA harvest?
Both harvests are same-day, in-clinic procedures under local anesthesia, and most patients describe the recovery as soreness rather than disability. After a BMA draw, the posterior pelvis is typically tender for several days, like a deep bruise. After an MFAT draw, the abdomen or flank site is sore and can bruise visibly for a week or two. Neither requires a hospital stay, general anesthesia, or an extended layoff, and the injection itself follows the same day. Activity guidance after the full Dynamic Stem Cell+ procedure is specific to the joint treated and is laid out by Dr. Garg before you leave, including when to resume walking, work, lifting, and sport. Individual recovery timelines vary with the site, the joint, and the patient.
Are BMAC and MFAT treatments FDA-approved?
No orthopedic stem cell injection in the United States is an FDA-approved drug therapy, and a clinic should say that plainly. BMA and MFAT procedures of the kind performed at Dynamic Athlete use your own tissue, harvested and returned to you the same day with minimal manipulation, inside the practice of medicine. That is a different category from donor-derived or laboratory-expanded cell products, some of which are marketed with claims the FDA has publicly warned about. The comparative studies cited on this page, including the randomized trials, were conducted with same-day autologous preparations of this kind. Ask any provider which category their product falls in, and be cautious of vials from a donor bank sold as stem cells for joints.